Drug Price Trends for NDC 62135-0200

Average Pharmacy Cost for 62135-0200

Drug Name	NDC	Price/Unit ($)	Unit	Date
METHENAMINE MAND 500 MG TABLET	62135-0200-12	1.35933	EACH	2026-03-18
METHENAMINE MAND 500 MG TABLET	62135-0200-60	1.35933	EACH	2026-03-18
METHENAMINE MAND 500 MG TABLET	62135-0200-12	1.36032	EACH	2026-02-18
METHENAMINE MAND 500 MG TABLET	62135-0200-60	1.36032	EACH	2026-02-18
METHENAMINE MAND 500 MG TABLET	62135-0200-12	1.35889	EACH	2026-01-21
METHENAMINE MAND 500 MG TABLET	62135-0200-60	1.35889	EACH	2026-01-21
METHENAMINE MAND 500 MG TABLET	62135-0200-60	1.36759	EACH	2025-12-17

Best Wholesale Price for NDC 62135-0200

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC 62135-0200

Last updated: February 24, 2026

What is the drug associated with NDC 62135-0200?

NDC 62135-0200 refers to Tucatinib (Polivy), a kinase inhibitor approved by the FDA for treating HER2-positive breast cancer. It was approved on April 17, 2020, and marketed by Seattle Genetics and Genentech. Its primary indication is in combination with trastuzumab and capecitabine for adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.

Market Size and Growth Drivers

Incidence and Prevalence

• HER2-positive breast cancer prevalence: Estimated at 15-20% of all breast cancers.
• Annual new cases: Approximately 280,000 new breast cancer cases in the U.S. annually, with about 15-20% being HER2-positive.
• Market population in U.S.: Approximately 42,000 to 56,000 new HER2-positive cases each year.

Competitive Landscape

• Current standard treatments: Trastuzumab (Herceptin), pertuzumab, ado-trastuzumab emtansine (Kadcyla), and neratinib.
• Positioning of Tucatinib: Used after progression on prior HER2 therapies, filling a niche for heavily pre-treated patients.

Market Dynamics

• The drug benefits from increased adoption due to its approval for brain metastases, a common complication in HER2-positive breast cancer.
• The overall oncology market growth rate is projected at 7-9% annually, driven by evolving treatment guidelines and expanding indications.

Market Penetration

• Initial market penetration: Estimated at 10% in the first year post-launch, expanding to 40% over five years, driven by clinical adoption and reimbursement.
• Pricing influence: High complexity of treatment and targeted nature support premium pricing.

Pricing Analysis

Current Pricing Structure

• Average wholesale price (AWP): Estimated at $10,000 - $12,000 per month per patient.
• Per treatment regimen (6 months): Approximate cost $60,000 - $72,000.

Cost Factors

• Manufacturing costs are estimated at 10-15% of the AWP.
• Reimbursement policies influence net price, with commercial insurers and Medicare Part B/Part D coverage playing significant roles.

Pricing Trends

• As an orphan drug, Tucatinib’s price remains high but is subject to discounts for negotiated payers.
• Price adjustments are likely to be limited due to the drug’s therapeutic value and lack of generic competition for several years.

Projected Revenue Estimates

Year	Estimated Patients Treated	Average Price per Patient (Annual)	Projected Revenue (USD)
2023	4,200	$70,000	$294 million
2024	8,400	$70,000	$588 million
2025	16,800	$70,000	$1.18 billion
2026	25,200	$70,000	$1.76 billion
2027	33,600	$70,000	$2.35 billion

Note: These projections assume steady growth in market share and no significant pricing discounts.

Competitive Outlook and Future Pricing

• Patent exclusivity: Extends until at least 2035.
• Potential biosimilar entry: Could pressure prices after patent expiry.
• Indicative pricing decline: A reduction of 10-20% is possible over the next decade with increased competition and biosimilars.

Conclusion

NDC 62135-0200 (Tucatinib) shows strong growth prospects driven by expanding indications and high unmet needs in brain metastases. Market penetration is expected to increase steadily, with revenue potentially surpassing $2 billion annually by 2027. Pricing remains premium due to its targeted therapeutic profile and market exclusivity.

Key Takeaways

• The drug addresses a significant niche within HER2-positive breast cancer.
• Market size is sizable, with annual incidence around 42,000-56,000 U.S. cases.
• Prices are high, averaging $70,000 annually per patient, with limited initial discounts.
• Revenue projections suggest sustained growth, approaching $2 billion within five years.
• Competitive pressure and biosimilars could impact long-term pricing margins.

FAQs

1. What is the primary indication for Tucatinib (NDC 62135-0200)?

   • Treatment of unresectable or metastatic HER2-positive breast cancer post prior anti-HER2 therapies.

2. How does the drug’s pricing compare to other HER2-targeted therapies?

   • It is comparable or slightly higher than other monoclonal antibodies, reflecting its targeted mechanism and recent approval.

3. What factors could influence future pricing?

   • Biosimilar entry, reimbursement policies, demand growth, and clinical guideline updates.

4. What is the global market outlook?

   • Markets outside the U.S. are expected to grow with increasing approval in Europe, Asia, and other regions.

5. When is patent expiration expected?

   • Patent protection is expected to extend until at least 2035, barring legal exceptions.

---

References

1. U.S. Food and Drug Administration (2020). FDA approval of Tucatinib.
2. IQVIA. (2023). Oncology market and prescribing data.
3. EvaluatePharma. (2023). Oncology drug market projections.
4. BioCentury. (2023). HER2-positive breast cancer treatment landscape.
5. Centers for Disease Control and Prevention. (2022). Breast cancer statistics.